Partial-EMT Signature Detection for HNSCC Metastasis Risk

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods struggle to effectively stratify patients with head and neck squamous cell carcinoma (HNSCC) based on molecular markers, particularly in diverse populations, leading to treatment challenges and health disparities due to high intra-tumoral heterogeneity and limited understanding of metastasis pathways.

Innovation Solution

A method involving the detection of a partial EMT (p-EMT) signature in malignant cells using genes such as SERPINE1, TGFB1, MMP10, LAMC2, P4HA2, PDPN, ITGA5, LAMA3, CDH13, TNC, MMP2, EMP3, INHBA, LAMB3, SNAIL2, and VIM to stratify patients into high or low risk groups, guiding personalized treatments like immunotherapy, chemoradiation, or lymph node dissection based on demographic-specific expression levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional multi-modal therapy is used for HNSCC treatment, then treatment coverage is comprehensive, but treatment effectiveness is limited due to incomplete understanding of molecular pathways

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidmolecular pathway understanding

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent implements feedback by using p-EMT signature detection to assess patient risk status, then adjusting treatment intensity and type based on this molecular information. High-risk patients receive intensified therapy while low-risk patients receive de-escalated therapy, creating a closed-loop system where treatment is continuously optimized based on molecular feedback

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent changes the parameter of treatment stratification from demographic/clinical parameters to molecular parameters (p-EMT signature expression levels). This enables differentiation of treatment approaches based on biological heterogeneity rather than uniform demographic categories, improving treatment precision

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If demographic-based treatment strategies are used, then treatment accessibility is improved, but health disparities persist due to high intra-tumoral heterogeneity

Engineering Contradiction:

Improvetreatment personalizationVSAvoidrisk stratification accuracy

Core Design Contradiction:

Adaptability or versatilityVSMeasurement precision

Solution Approach 1:

The patent introduces the p-EMT signature as an intermediary molecular marker that bridges demographic categories and treatment responses. Rather than treating demographics directly, the patent uses p-EMT expression as a mediator that captures the underlying biological heterogeneity driving treatment outcomes across different population groups

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies local quality by identifying that different demographic groups have distinct p-EMT expression patterns and establishing demographic-specific risk thresholds. This enables tailored risk assessment for each population group (e.g., different cutoff values for African American vs. Caucasian patients) rather than applying uniform standards

Inventive Principle:

Principle #3Local quality

3Reliability

If intensive treatment is applied to all patients, then treatment coverage is maximized, but quality of life is compromised due to excessive treatment intensity

Engineering Contradiction:

Improvesurvival outcomeVSAvoidtreatment toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies partial action by providing de-escalated therapy to low-risk patients who do not require maximum treatment intensity. These patients receive reduced treatment (e.g., observation instead of adjuvant therapy, or reduced-dose regimens) that is sufficient for their lower risk profile, avoiding the excessive treatment toxicity that would harm their quality of life

Inventive Principle:

Principle #16Partial or excessive action

4Ease of manufacture

If uniform treatment protocols are used across all populations, then treatment standardization is achieved, but treatment efficacy varies due to racial and ethnic differences

Engineering Contradiction:

Improvetreatment standardizationVSAvoidtreatment efficacy

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent changes the stratification parameter from demographic categories to molecular parameters (p-EMT signature). This allows treatment protocols to be standardized based on biological response patterns rather than demographic labels, improving efficacy while maintaining implementability through objective molecular testing

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250327128A1Partial-EMT signature for prediction of high-risk histopathologic features and cancer outcomes across demographic populations

Publication Date: 2025.10.23 THE BROAD INST INC

AI summary

The present invention advantageously provides for use of a p-EMT signature for the treatment and prognosis of head and neck cancer across demographic groups. The p-EMT signature is differentially expressed across demographic groups. The p-EMT state indicates a high risk of metastasis and adverse clinical features that may be used to direct treatment of head and neck cancer.